Europe
The firm, which has revealed profits of £990,837, claims it is the disruptive force in the IP-legal industry
In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of clinical trial protocols occurs before the application's filing date
Practitioners and law firms should keep their eyes peeled for the shortlists for our annual awards
Despite a broader slowdown in US IP partner hiring in 2025, litigation demand drove aggressive lateral expansion at select firms
Sponsored
Sponsored
-
Sponsored by Slaughter and MayDavid Ives, Laura Houston, and Richard Barker of Slaughter and May examine the UK High Court’s ruling and assess its implications for AI developers, rights holders, and future appeals
-
Sponsored by Maiwald Intellectual PropertyMarco Stief of Maiwald argues that the District Court of The Hague missed an opportunity to clarify the uncertainty surrounding the term ‘first authorisation’ in Article 3(d) of the SPC Regulation in a recent judgment
-
Sponsored by Gün and PartnersThe ruling addresses the impact of device mark differences, proof of use, and well-known status arguments, say Hande Hançar Koç, Havva Yıldız, and Zeynep Berfin Ekinci of Gün and Partners
-
Sponsored by InspicosJakob Pade Frederiksen of Inspicos highlights how a recent ruling relating to the applicable standard for inventive step assessment diverges from the EPO’s problem-solution approach
-
Sponsored by InventaSpain’s Donut case shows how widespread linguistic use does not necessarily erode trademark rights. Diogo Antunes of Inventa examines how Spanish and Portuguese practice address lexicalisation, reputation, and the boundary between descriptiveness and genericide
-
Sponsored by Patrinos & KilimirisMaria Kilimiris of Patrinos & Kilimiris explains how an interim ruling concerning the likelihood of confusion between Fenistil and Knistil highlights how pharmaceutical trademarks and product get-up are assessed under EU and national law
European Jurisdictions